Sanofi and Regeneron Report Five-Year LIBERTY AD CHRONOS Data for Dupixent in Atopic Dermatitis

Sanofi and Regeneron today presented five-year follow-up data from the Phase 3 LIBERTY AD CHRONOS trial evaluating Dupixent (dupilumab) in patients with moderate-to-severe atopic dermatitis. The data showed that the skin clearance benefits of Dupixent were maintained over five years of treatment, with approximately 65% of patients achieving IGA 0/1 response at five years.